

## Aetna P4P 2018 Measures

Measure	Measure Description	Comments	
Breast Cancer Screening	The percentage of women 50-75 years of age who had a mammogram to screen for breast cancer within the measurement period or 15 months prior to the start of the measurement period	Minimum of one mammogram every 27 months with results documented in EHR	
	Exclusions: Bilateral mastectomy or right and left unilateral mastectomy		
Diabetes: Hemoglobin A1c Testing	The percentage of patients 18-75 years of age with diabetes (type 1 and type 2) who received an HbA1c test during the measurement period	Minimum of one HbA1c test during the measurement year with results documented in EHR	
	Exclusions/Exceptions: Patients with a diagnosis of polycystic ovaries, gestational or steroid induced diabetes. Patients that did not have a face-to-face encounter with a diagnosis of diabetes.		
Diabetes: Medical Attention for Nephropathy	The percentage of patients 18-75 years of age with diabetes (type 1 and type 2) who received a nephropathy screening or monitoring test or had evidence of nephropathy during the measurement period	Nephropathy screening or monitoring tests include:	
		CPT Code	Description
		81000-81005	Urinalysis
		82042-82044	Urine Albumin/Microalbumin
	Evidence of nephropathy treatment captured through visit to a nephrologist or through active prescription of an ACE or ARB medication during the measurement period		
Exclusions/Exceptions: Patients with a diagnosis of polycystic ovaries, gestational or steroid induced diabetes. Patients that did not have a face-to-face encounter with a diagnosis of diabetes.			
Diabetes: Hemoglobin A1c Poor Control	The percentage of patients 18-75 years of age with diabetes (type 1 and type 2) that demonstrate poor glycemic control, based on an HbA1c level > 9.0%	Most recent A1c in 2018 < 9.0%	
		Must have A1c blood work for 2018 noted in chart	
		Tip: Document results in labs section and, if scanned results, in patient documents in EHR	
	Exclusions/Exceptions: Patients with a diagnosis of polycystic ovaries, gestational or steroid induced diabetes. Patients that did not have a face-to-face encounter with a diagnosis of diabetes.		
Persistent Medication Use with Lab Monitoring: Digoxin, ACE-I/ARB or Diuretic	The percentage of members 18 years of age and older who received at least a 180-day supply of digoxin, ACE-I/ARB or diuretic and therapeutic monitoring testing during the measurement period	Digoxin – pick 1 of the following	
		ACE-I/ARB or diuretic – pick 1 of the following	
	Exclusions: Patients who had an inpatient stay (acute or non-acute) during the measurement period.		
Well Child Visits 3-6 Years of Life	The percentage of patients 3-6 years of age that received at least 1 well child visit during the measurement period	CPT Code	Description
		Initial comprehensive preventive medicine	
		99382	New patient; early childhood (age 1-4)
		99383	New patient; late childhood (age 5-11)
		Periodic comprehensive preventive medicine	
		99392	Established patient; early childhood (age 1-4)
		99393	Established patient; late childhood (age 5-11)



## Aetna P4P 2018 Measures

Measure	Measure Description	Comments
Generic Substitution	For RX claims ordered by a specific provider that are generic or have a generic equivalent, the percentage that are generic or unknown generic status medications	
	<b>Exclusions:</b> Levothyroxine sodium, cardiac glycosides, clozapine, hydantoins, Coumadin anticoagulants	
In-Network Laboratory Use	The percentage of laboratory studies ordered by the provider or group that are performed in an in-network laboratory facility	<b>Quest Diagnostics</b> is Aetna's national preferred lab for all Aetna insurance products
		Non-HMO Aetna members can also visit <b>FMH Laboratory Services</b> for in-network service